Uwe Haberkorn

46.1k total citations · 22 hit papers
517 papers, 31.2k citations indexed

About

Uwe Haberkorn is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Uwe Haberkorn has authored 517 papers receiving a total of 31.2k indexed citations (citations by other indexed papers that have themselves been cited), including 300 papers in Radiology, Nuclear Medicine and Imaging, 179 papers in Oncology and 177 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Uwe Haberkorn's work include Radiopharmaceutical Chemistry and Applications (193 papers), Prostate Cancer Treatment and Research (126 papers) and Medical Imaging Techniques and Applications (114 papers). Uwe Haberkorn is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (193 papers), Prostate Cancer Treatment and Research (126 papers) and Medical Imaging Techniques and Applications (114 papers). Uwe Haberkorn collaborates with scholars based in Germany, United States and Switzerland. Uwe Haberkorn's co-authors include Frederik L. Giesel, Clemens Kratochwil, Walter Mier, Klaus Kopka, Matthias Eder, Jürgen Debus, Ali Afshar‐Oromieh, Michael Eisenhut, Annette Altmann and Martin Schäfer and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Uwe Haberkorn

510 papers receiving 30.8k citations

Hit Papers

68Ga-FAPI PET/CT: Tracer Uptake in 28 Diffe... 2012 2026 2016 2021 2019 2014 2016 2013 2012 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
    2019 964 citations Clemens Kratochwil, Paul Flechsig et al. Journal of Nuclear Medicine profile →
  2. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
    2014 785 citations Ali Afshar‐Oromieh, Frederik L. Giesel et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
  3. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
    2016 773 citations Clemens Kratochwil, Frank Bruchertseifer et al. Journal of Nuclear Medicine profile →
  4. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
    2013 712 citations Ali Afshar‐Oromieh, Matthias Eder et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
  5. 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
    2012 688 citations Matthias Eder, Martin Schäfer et al. profile →
  6. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
    2018 644 citations Thomas Lindner, Anastasia Loktev et al. Journal of Nuclear Medicine profile →
  7. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
    2017 567 citations Frederik L. Giesel, Uwe Haberkorn et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
  8. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
    2018 534 citations Anastasia Loktev, Thomas Lindner et al. Journal of Nuclear Medicine profile →
  9. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
    2018 488 citations Frederik L. Giesel, Clemens Kratochwil et al. Journal of Nuclear Medicine profile →
  10. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
    2015 464 citations Martin Schäfer, Ulrike Bauder‐Wüst et al. Journal of Nuclear Medicine profile →
  11. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
    2016 463 citations Clemens Kratochwil, Frederik L. Giesel et al. Journal of Nuclear Medicine profile →
  12. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
    2016 441 citations Frederik L. Giesel, Boris Hadaschik et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
  13. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
    2017 400 citations Ali Afshar‐Oromieh, Tim Holland‐Letz et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
  14. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
    2017 378 citations Clemens Kratochwil, Frank Bruchertseifer et al. Journal of Nuclear Medicine profile →
  15. Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
    2019 370 citations Anastasia Loktev, Thomas Lindner et al. Journal of Nuclear Medicine profile →
  16. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
    2015 332 citations Ali Afshar‐Oromieh, Clemens Kratochwil et al. Journal of Nuclear Medicine profile →
  17. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
    2014 317 citations Matthias Eder, Ulrike Bauder‐Wüst et al. profile →
  18. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
    2014 315 citations Clemens Kratochwil, Frederik L. Giesel et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
  19. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
    2018 314 citations Clemens Kratochwil, Frank Bruchertseifer et al. Journal of Nuclear Medicine profile →
  20. Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
    2018 248 citations Frederik L. Giesel, Paul Flechsig et al. Journal of Nuclear Medicine profile →
  21. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
    2021 214 citations Uwe Haberkorn et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
  22. FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease
    2023 177 citations Clemens Kratochwil, Frederik L. Giesel et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Uwe Haberkorn Germany 91 17.4k 13.4k 12.3k 4.8k 4.6k 517 31.2k
Rodney J. Hicks Australia 78 11.3k 0.6× 8.5k 0.6× 7.7k 0.6× 2.6k 0.5× 2.0k 0.4× 602 23.8k
Denis Lacombe Belgium 34 7.1k 0.4× 14.2k 1.1× 15.2k 1.2× 7.7k 1.6× 9.2k 2.0× 113 41.0k
Elizabeth A. Eisenhauer Canada 61 5.4k 0.3× 12.7k 1.0× 15.2k 1.2× 7.3k 1.5× 12.0k 2.6× 213 41.9k
Patrick Y. Wen United States 102 7.3k 0.4× 11.6k 0.9× 9.9k 0.8× 8.0k 1.7× 12.3k 2.7× 781 43.2k
Roger Stupp Switzerland 85 8.2k 0.5× 13.9k 1.0× 9.5k 0.8× 10.7k 2.2× 15.7k 3.4× 376 49.8k
Martin J. van den Bent Netherlands 92 10.3k 0.6× 14.9k 1.1× 8.1k 0.7× 9.9k 2.0× 12.7k 2.8× 579 51.0k
Robert B. Jenkins United States 89 5.1k 0.3× 10.0k 0.7× 11.2k 0.9× 11.5k 2.4× 13.0k 2.9× 400 34.9k
Raymond Sawaya United States 84 3.7k 0.2× 7.2k 0.5× 7.9k 0.6× 5.0k 1.0× 8.4k 1.8× 351 28.2k
Zvi Fuks United States 96 6.2k 0.4× 11.2k 0.8× 5.3k 0.4× 2.8k 0.6× 10.6k 2.3× 405 32.0k
Walter Mier Germany 61 6.6k 0.4× 4.7k 0.4× 5.8k 0.5× 2.3k 0.5× 3.8k 0.8× 243 15.1k

Countries citing papers authored by Uwe Haberkorn

Since Specialization
Citations

This map shows the geographic impact of Uwe Haberkorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uwe Haberkorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uwe Haberkorn more than expected).

Fields of papers citing papers by Uwe Haberkorn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uwe Haberkorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uwe Haberkorn. The network helps show where Uwe Haberkorn may publish in the future.

Co-authorship network of co-authors of Uwe Haberkorn

This figure shows the co-authorship network connecting the top 25 collaborators of Uwe Haberkorn. A scholar is included among the top collaborators of Uwe Haberkorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uwe Haberkorn. Uwe Haberkorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Röhrich, Manuel, Norbert Blank, Daniel Paech, et al.. (2024). Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission. Lara D. Veeken. 63(9). 2473–2483. 11 indexed citations
2.
Haberkorn, Uwe, Annette Altmann, Frederik L. Giesel, & Clemens Kratochwil. (2024). 1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening?. Journal of Nuclear Medicine. 65(10). 1518–1520. 5 indexed citations
3.
Rathke, Hendrik, Frank Bruchertseifer, Manuel Röhrich, et al.. (2024). Deescalated225Ac-PSMA-617 Versus177Lu/225Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients. Journal of Nuclear Medicine. 65(7). 1057–1063. 12 indexed citations
4.
Rathke, Hendrik, Stefan Fuxius, Frederik L. Giesel, et al.. (2021). Two Tumors, One Target. Clinical Nuclear Medicine. 46(10). 842–844. 30 indexed citations
5.
Matthias, Jessica, Johann Engelhardt, Martin Schäfer, et al.. (2021). Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. Cancer Research. 81(8). 2234–2245. 21 indexed citations
6.
Altmann, Annette, Uwe Haberkorn, & Jens T. Siveke. (2020). The Latest Developments in Imaging of Fibroblast Activation Protein. Journal of Nuclear Medicine. 62(2). 160–167. 180 indexed citations
7.
Windisch, Paul, Daniel R. Zwahlen, Stefan A. Koerber, et al.. (2020). Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review. Cancers. 12(9). 2629–2629. 33 indexed citations
8.
Eder, Matthias, Silvia Pavan, Ulrike Bauder‐Wüst, et al.. (2019). Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors. Cancer Research. 79(4). 841–852. 49 indexed citations
9.
Chiblak, Sara, Zili Tang, Dieter Lemke, et al.. (2019). Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. JCI Insight. 4(2). 60 indexed citations
10.
Röhrich, Manuel, Anastasia Loktev, Annika K. Wefers, et al.. (2019). IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 46(12). 2569–2580. 110 indexed citations
11.
Zacho, Helle D., Ali Afshar‐Oromieh, Uwe Haberkorn, et al.. (2018). Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 45(11). 1884–1897. 71 indexed citations
12.
Altmann, Annette, Max Sauter, Saskia Roesch, et al.. (2017). Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display. Clinical Cancer Research. 23(15). 4170–4180. 45 indexed citations
13.
Schäfer, Martin, Ulrike Bauder‐Wüst, Mareike Roscher, et al.. (2017). PSMA-11–Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer. Journal of Nuclear Medicine. 59(4). 639–645. 101 indexed citations
14.
Weber, Justus, Uwe Haberkorn, & Walter Mier. (2015). Cancer Stratification by Molecular Imaging. International Journal of Molecular Sciences. 16(3). 4918–4946. 21 indexed citations
15.
Kratochwil, Clemens, M. Stefanova, Eleni Mavriopoulou, et al.. (2014). SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. Molecular Imaging and Biology. 17(3). 313–318. 165 indexed citations
16.
Askoxylakis, Vasileios, Gunda Millonig, Ute Wirkner, et al.. (2011). Investigation of tumor hypoxia using a two-enzyme system for in vitro generation of oxygen deficiency. Radiation Oncology. 6(1). 35–35. 17 indexed citations
17.
Zitzmann-Kolbe, Sabine, Susanne Krämer, Christel Herold‐Mende, et al.. (2009). Identification and Characterization of a Peptide with Affinity to Head and Neck Cancer. Journal of Nuclear Medicine. 50(3). 426–434. 37 indexed citations
18.
Strauss, Ludwig G., Dirk Koczan, Leyun Pan, et al.. (2008). Impact of Angiogenesis-Related Gene Expression on the Tracer Kinetics of18F-FDG in Colorectal Tumors. Journal of Nuclear Medicine. 49(8). 1238–1244. 49 indexed citations
19.
Hoffend, Johannes, et al.. (2003). 99mTcO(BAT-NI), a novel nitroimidazole tracer: in vivo uptake studies in ischaemic myocardium. European Journal of Nuclear Medicine and Molecular Imaging. 30(4). 494–501. 6 indexed citations
20.
Reißer, Ch., Uwe Haberkorn, Antonia Dimitrakopoulou‐Strauss, Eberhard Seifert, & Ludwig G. Strauss. (1995). Chemotherapeutic Management of Head and Neck Malignancies With Positron Emission Tomography. Archives of Otolaryngology - Head and Neck Surgery. 121(3). 272–276. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rodney J. Hicks Breakdown of academic impact, for papers by Denis Lacombe Breakdown of academic impact, for papers by Elizabeth A. Eisenhauer Breakdown of academic impact, for papers by Patrick Y. Wen Breakdown of academic impact, for papers by Roger Stupp Breakdown of academic impact, for papers by Martin J. van den Bent Breakdown of academic impact, for papers by Robert B. Jenkins Breakdown of academic impact, for papers by Raymond Sawaya Breakdown of academic impact, for papers by Zvi Fuks Breakdown of academic impact, for papers by Walter Mier
Rankless by CCL
2026